Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • Pfizer, AstraZeneca...

Pfizer, AstraZeneca and several other drugmakers in race to join weight loss drug market

Ruchika SharmaWritten by Ruchika Sharma Published On 2024-12-23T17:01:47+05:30  |  Updated On 23 Dec 2024 5:01 PM IST
Alembic Pharma gets USFDA nod for cardio drug Rivaroxaban
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Pfizer, AstraZeneca, Amgen and several other drug developers aiming to join the weight-loss drug market, which is estimated to be worth about $150 billion by the early 2030s. Novo Nordisk's Wegovy and Eli Lilly's Zepbound are so far the leaders in this market.

According to Reuters, the following is a list of publicly listed companies targeting the next big blockbuster opportunity:

NOVO NORDISK

Novo's closely-watched obesity drug candidate CagriSema helped overweight patients cut their weight by 22.7% in a late-stage trial, but that was below its own expectations of up to 25% reduction.
The data compares to weight loss of about 15% after 68 weeks in a trial for Wegovy.
CagriSema is a weekly injection, which combines semaglutide, the active ingredient in Wegovy and mimics the gut hormone GLP-1, and a separate molecule called cagrilintide that mimics the pancreatic hormone amylin.
The two hormones combined suppress hunger and help control patients' blood glucose.
Novo is also developing a weight-loss pill, amycretin, which helped obese participants lose 13.1% of their weight after 12 weeks of treatment in an early-stage study.
The company said in September it plans to decide on further studies for amycretin after data from an early study on a subcutaneous version of the drug, which is expected next year.
It is set to buy three of contract drug manufacturer Catalent's fill-finish sites in Italy, Belgium and the U.S. to help boost Wegovy's production.
Novo Holdings, the controlling shareholder of Novo Nordisk, completed its acquisition of Catalent on Dec. 18.

ELI LILLY

Eli Lilly's weight-loss therapy, Zepbound, got the green light from the U.S. and UK regulators last year, paving the way for a powerful new rival to Novo's Wegovy.
Earlier in December, Lilly said patients taking Zepbound lost 47% more weight than those who were given Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.
In the 751-person trial sponsored by Lilly, Zepbound helped patients lose an average of 20.2% of their weight after 72 weeks compared to 13.7% for the group treated with Wegovy.
In 2023, Lilly had said a mid-stage trial of its next-generation obesity drug candidate, a once-weekly injection of retatrutide, led to weight loss of up to 24.2% after 48 weeks.
Lilly is currently testing retatrutide in late-stage trials.
It is testing another experimental obesity pill, orforglipron, in a late-stage trial and expects to disclose data from the study in April 2025.
The highest dose of orforglipron led to 14.7% weight loss after 36 weeks in obese patients, data from a mid-stage trial had showed.

PFIZER

In July, Pfizer said it planned to enter clinical trials later this year for a reworked, once-a-day version of its weight-loss pill, danuglipron.
The drugmaker said last year it was stopping further trials of a twice-daily version of danuglipron.

ROCHE AND CARMOT THERAPEUTICS

Roche acquired CT-388 as part of its $2.7 billion buyout of Carmot Therapeutics. Carmot's once-a-week injection belongs to the same class as Eli Lilly's Mounjaro, or Zepbound.
In July, the company announced that a second drug candidate from its purchase of Carmot yielded positive results in an early-stage trial.
Roche said its experimental pill, which could appeal to patients averse to injections, was well tolerated with mostly mild or moderate gastrointestinal side effects similar to those seen in other weight-loss drugs.

AMGEN

In November, Amgen's closely-watched experimental obesity drug MariTide helped overweight patients shed up to 20%of their body weight in an year-long mid-stage trial.
Analysts said MariTide's weight-loss benefit was in line with Wegovy and Zepbound, but had slightly more side effects.

MERCK

In December, Merck signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's experimental oral drug to treat obesity, becoming a late contender in the race to offer a weight-loss pill to replace weekly shots.
The drug, HS-10535, is a GLP-1 receptor agonist candidate similar to Wegovy and Zepbound.

ASTRAZENECA

AstraZeneca's experimental weight-loss pill, licensed a year ago from China's Eccogene for up to $2 billion, was found to be safe and tolerable in an early-stage trial in November.
The drugmaker said it has progressed the once-daily pill, called AZD5004, into mid-stage trials.

ALTIMMUNE

Altimmune said last year its drug candidate, pemvidutide, helped reduce weight by 15.6% on average and showed continued weight loss at the end of treatment in a mid-stage trial.
Patients, however, also experienced nausea and vomiting of mild and moderate severity.

VIKING THERAPEUTICS

Viking Therapeutics said in February its experimental drug, VK2735, helped patients achieve up to 14.7% mean weight loss after 13 weeks of treatment in a mid-stage study, which had enrolled 176 overweight adults with at least one weight-related comorbidity.
In November, the company said the drug helped nine patients, who received the highest 100 milligram dose, lose an average of 8.2% of their body weight after 28 days in an early-stage trial.

ZEALAND PHARMA

Danish biotech Zealand Pharma said in June a high dose of its weight-loss drug candidate petrelintide helped reduce weight by an average 8.6% after 16 weekly doses in an early-stage study.
The company said in August it is set to start talks with other pharmaceutical companies in the second half of this year for potential partnerships to develop and commercialize petrelintide.
Zealand is currently testing petrelintide in overweight or obese individuals without type 2 diabetes in a mid-stage study.

STRUCTURE THERAPEUTICS

Structure Therapeutics said in June its experimental oral obesity drug helped reduce weight by 6.2% on average at the end of 12 weeks in a mid-stage study.

Read also: Tirzepatide versus Semaglutide- Surmount-5 trial reveals head-on comparison results


novo nordisknovo nordisk newswegovyeli lillyeli lilly newszepboundweight lossCagriSemasemaglutideamycretinZepboundretatrutideorforgliprondanuglipronpfizerrocheMariTideamgenmerckHansoh Pharmaastrazenecapemvidutide
Source : with inputs
Ruchika Sharma
Ruchika Sharma

    Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    View All

    Journal Club Today

    Study Reveals Why Your Immune System Works Better in Daylight

    Study Reveals Why Your Immune System Works Better in Daylight

    View All

    Health News Today

    Health Bulletin 28/May/2025

    Health Bulletin 28/May/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok